NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) | PA 20 194

Frequently Asked Questions (FAQs)

What is the NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) (PA-20-194)?

PA-20-194 is an NIH discretionary grant opportunity using the R21 mechanism to support early-stage, exploratory, and developmental research projects. It is designed for high-potential ideas that may still be conceptual and may not yet have extensive preliminary data, especially when the work involves meaningful scientific risk but could lead to major advances or open new research directions.

What is the funding opportunity number for this program?

The funding opportunity number is PA-20-194.

Which agency is offering this grant opportunity?

The agency is the National Institutes of Health (NIH).

What type of funding instrument is this opportunity?

The funding instrument is a grant.

What is the purpose of the R21 mechanism in this announcement?

This R21 is meant to help investigators launch early-stage, high-potential projects, particularly exploratory or developmental studies where the concept is emerging and extensive preliminary data may not be available yet. NIH positions it to support scientifically risky work that could produce a major advance, open a new line of investigation, or generate broadly useful research outputs.

Are clinical trials required under this Parent R21 announcement?

Yes. A central requirement of this specific Parent R21 announcement is that the application must propose at least one clinical trial. Applicants need to ensure the study meets the NIH definition of a clinical trial and includes appropriate trial-related planning and oversight elements.

What does NIH mean by a "clinical trial" for this opportunity?

The opportunity states that applicants must ensure their study meets the NIH definition of a clinical trial. The details of that definition are not included in the provided excerpt, but the key requirement here is that the proposed work must qualify as at least one clinical trial under NIH rules.

Do all NIH Institutes and Centers (ICs) accept any type of clinical trial under this announcement?

Not necessarily. NIH notes that some participating Institutes and Centers will only accept applications under this announcement if the proposed work is a mechanistic study that still qualifies as a clinical trial under NIH rules. Because IC policies can differ, applicants should pay close attention to institute-specific limitations described in related notices and align the application with the relevant IC's expectations.

What is a key strategy for submitting a strong application under PA-20-194?

Based on the information provided, a strong application typically aligns tightly with the mission and programmatic priorities of at least one participating NIH Institute or Center and checks for any institute-specific limitations or requirements referenced in related notices.

What research areas are supported by this program?

The program is broad in scientific scope and can cover biomedical, behavioral, and clinical research areas, as long as the topic fits within the interests of one or more participating NIH Institutes and Centers.

What kinds of outcomes does NIH hope to catalyze through this R21 opportunity?

NIH highlights outcomes such as breakthrough findings, novel techniques, new agents or interventions, innovative methodologies, improved models, or new applications that could significantly influence a field. The opportunity emphasizes novel, potentially field-shaping work that is ready to be tested in humans through a clinical trial framework, even if the underlying idea is still emerging.

Is extensive preliminary data required to apply?

The R21 is described as being appropriate for ideas still in the conceptual phase and may not yet have extensive preliminary data. The emphasis is on exploratory and developmental work with potential for significant impact.

Who is eligible to apply?

Eligibility is expansive. The provided information lists many eligible entities, including a wide range of U.S. organizations and governmental entities, nonprofit and for-profit organizations, small businesses, higher education institutions, tribal entities, and additional categories often emphasized for outreach and inclusion.

Which types of government entities are eligible?

Examples listed include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.

Are colleges and universities eligible?

Yes. The opportunity includes public and state-controlled institutions of higher education and private institutions of higher education among eligible applicants.

Are tribal governments and tribal organizations eligible?

Yes. The eligibility list includes federally recognized Native American tribal governments and Native American tribal organizations other than federally recognized tribal governments. It also mentions Indian/Native American Tribal Governments other than federally recognized entities.

Are nonprofit organizations eligible?

Yes. The announcement allows nonprofit organizations with or without 501(c)(3) status.

Are for-profit organizations eligible?

Yes. The opportunity allows for-profit organizations other than small businesses, and it also explicitly includes small businesses.

Are foreign (non-U.S.) organizations eligible to apply?

Yes. The eligibility list includes non-domestic (non-U.S.) entities (foreign organizations).

Are applicants from U.S. territories or possessions eligible?

Yes. The eligibility list includes applicants from a U.S. territory or possession.

Does the announcement highlight any institution types for outreach and inclusion?

Yes. The provided list mentions Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), and also faith-based or community-based organizations.

Are federal agencies eligible to apply?

Yes. The provided eligibility details include eligible federal agencies.

What is the activity category listed for this opportunity?

The activity category is listed as Education, Environment, Health.

Are there Assistance Listing (CFDA) numbers associated with this opportunity?

Yes. Multiple Assistance Listing numbers are associated with the opportunity: 93.113, 93.172, 93.173, 93.242, 93.273, 93.279, 93.361, 93.846, 93.855, 93.866, and 93.867.

Why are multiple Assistance Listing numbers associated with a single parent announcement?

The excerpt explains that multiple NIH institutes and programs may participate under this parent announcement, and the multiple Assistance Listing numbers reflect that broader participation across NIH.

What is the original closing date shown for this opportunity?

The posting shows an original closing date of 2025-01-07.

What is the creation date shown for this opportunity?

The posting shows a creation date of 2020-05-07.

Is the award ceiling provided in the excerpt?

No. The award ceiling is not specified in the provided excerpt.

Is the expected number of awards provided in the excerpt?

No. The expected number of awards is not specified in the provided excerpt.

Why might award amounts and number of awards be unspecified for this kind of NIH opportunity?

The excerpt notes this is common for NIH parent announcements, where budgets and award counts can depend on institute participation, application volume, and available appropriations.

In plain terms, who is this opportunity best suited for?

Based on the provided information, this opportunity is best suited for investigators who want to test bold, early-stage ideas in a clinical trial setting and who can clearly align their proposal with the priorities and any special submission rules of the most relevant NIH Institute or Center.